The Burden of Gout and Its Attributable Risk Factors in the Middle East and North Africa Region, 1990 to 2019

REFERENCES

1. 1.↵
   1. Faires J,
   2. McCarty D.

   Acute arthritis in man and dog after intrasynovial injection of sodium urate crystals. Lancet 1962;280:682-5.

   OpenUrlCrossRef
2. 2.↵
   1. Bursill D,
   2. Taylor WJ,
   3. Terkeltaub R, et al.

   Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis 2019;78:1592-600.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Kuo CF,
   2. Grainge MJ,
   3. Zhang W,
   4. Doherty M.

   Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 2015;11:649-62.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Dalbeth N,
   2. Pool B,
   3. Gamble GD, et al.

   Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum 2010;62:1549-56.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Neuwirth E.

   Milestones in the diagnosis and treatment of gout. Arch Intern Med 1943;72:377-87.

   OpenUrlCrossRef
6. 6.↵
   1. Boss GR,
   2. Seegmiller JE.

   Hyperuricemia and gout. N Engl J Med 1979;300:1459-68.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Smith E,
   2. Hoy D,
   3. Cross M, et al.

   The global burden of gout: Estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014;73:1470-6.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Safiri S,
   2. Kolahi AA,
   3. Cross M, et al.

   Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990-2017: A systematic analysis of the Global Burden of Disease Study 2017. Arthritis Rheum 2020;72:1916-27.

   OpenUrl
9. 9.↵
   1. Rai SK,
   2. Burns LC,
   3. De Vera MA,
   4. Haji A,
   5. Giustini D,
   6. Choi HK.

   The economic burden of gout: A systematic review. Semin Arthritis Rheum 2015;45:75-80.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. GBD 2019 Risk Factors Collaborators

    . Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1223-49.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. GBD 2019 Diseases and Injuries Collaborators

    . Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1204-22.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. GBD 2019 Demographics Collaborators

    . Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1160-203.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Wallace SL,
    2. Robinson H,
    3. Masi AT,
    4. Decker JL,
    5. McCarty DJ,
    6. Yü TF.

    Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Edwards NL,
    2. Sundy JS,
    3. Forsythe A,
    4. Blume S,
    5. Pan F,
    6. Becker MA.

    Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ 2011;14:10-15.

    OpenUrlCrossRefPubMed
15. 15.
    1. Yu KH,
    2. Luo SF.

    Younger age of onset of gout in Taiwan. Rheumatology 2003;42:166-70.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Yu TF.

    Diversity of clinical features in gouty arthritis. Semin Arthritis Rheum 1984;13:360-8.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Wang Y.

    Smoothing splines: methods and applications. London: Chapman and Hall/CRC; 2019.
18. 18.↵
    1. Smith E,
    2. March L.

    Global prevalence of hyperuricemia: A systematic review of population-based epidemiological studies [abstract]. Arthritis Rheumatol 2015;67 (suppl 10).
19. 19.↵
    1. Smith EUR,
    2. Díaz-Torné C,
    3. Perez-Ruiz F,
    4. March LM.

    Epidemiology of gout: An update. Best Pract Res Clin Rheumatol 2010;24:811-27.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Dai H,
    2. Alsalhe TA,
    3. Chalghaf N,
    4. Riccò M,
    5. Bragazzi NL,
    6. Wu J.

    The global burden of disease attributable to high body mass index in 195 countries and territories, 1990-2017: An analysis of the Global Burden of Disease Study. PLoS Med 2020;17:e1003198.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. GBD Chronic Kidney Disease Collaboration

    . Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020;395:709-33.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Jha V,
    2. Garcia-Garcia G,
    3. Iseki K, et al.

    Chronic kidney disease: Global dimension and perspectives. Lancet 2013;382:260-72.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Sung H,
    2. Siegel RL,
    3. Torre LA, et al.

    Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin 2019;69:88-112.

    OpenUrlPubMed
24. 24.↵
    1. Xia Y,
    2. Wu Q,
    3. Wang H, et al.

    Global, regional and national burden of gout, 1990-2017: A systematic analysis of the Global Burden of Disease Study. Rheumatology 2020;59:1529-38.

    OpenUrlPubMed
25. 25.↵
    1. Al-Thani M,
    2. Al-Thani A,
    3. Alyafei S, et al.

    The prevalence and characteristics of overweight and obesity among students in Qatar. Public Health 2018;160:143-9.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Ali FM,
    2. Nikoloski Z,
    3. Reka H,
    4. Gjebrea O,
    5. Mossialos E.

    The diabetes-obesity-hypertension nexus in Qatar: Evidence from the World Health Survey. Popul Health Metr 2014;12:18.

    OpenUrlPubMed
27. 27.↵
    1. ALNohair S.

    Obesity in gulf countries. Int J Health Sci 2014; 8:79-83.

    OpenUrlPubMed
28. 28.↵
    1. Kelishadi R,
    2. Pour MH,
    3. Sarraf-Zadegan N, et al.

    Obesity and associated modifiable environmental factors in Iranian adolescents: Isfahan Healthy Heart Program - Heart Health Promotion from Childhood. Pediatr Int 2003;45:435-42.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Thompson MD,
    2. Wu YY,
    3. Cooney RV,
    4. Wilkens LR,
    5. Haiman CA,
    6. Pirkle CM.

    Modifiable factors and incident gout across ethnicity within a large multiethnic cohort of older adults. J Rheumatol 2022;49:504-12.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Afshin A,
    2. Forouzanfar MH,
    3. Reitsma MB, et al; GBD 2015 Obesity Collaborators

    . Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med 2017;377:13-27.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Joosten LAB,
    2. Netea MG,
    3. Mylona E, et al.

    Engagement of fatty acids with toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal–induced gouty arthritis. Arthritis Rheum 2010;62:3237-48.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Dirken-Heukensfeldt KJ,
    2. Teunissen TA,
    3. van de Lisdonk H,
    4. Lagro-Janssen AL.

    “Clinical features of women with gout arthritis.” A systematic review. Clin Rheumatol 2010;29:575-82.

    OpenUrlPubMed
33. 33.↵
    1. Safiri S,
    2. Kolahi AA,
    3. Cross M, et al.

    Prevalence, deaths, and disability-adjusted life years due to musculoskeletal disorders for 195 countries and territories 1990-2017. Arthritis Rheumatol 2021;73:702-14.

    OpenUrl
34. 34.↵
    1. Kazeminasab S,
    2. Nejadghaderi SA,
    3. Amiri P, et al.

    Neck pain: Global epidemiology, trends and risk factors. BMC Musculoskelet Disord 2022;23:26.

    OpenUrlCrossRef